L'Écho : grand quotidien d'information du Centre Ouest

14 juin 19231923/06/14 (A52).Appartient à l’ensemble documentaire : PoitouCh

Additional file 2: Figure S2. of APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice

Regional analysis of perivascular hemosiderin deposits identifies the brain cortex in mice of all APOE genotypes and the thalamus in APP/ε2 mice as brain structures susceptible to microbleeds associated with anti-Aβ immunization. Shown are means (± SEM) for counts of all brain perivascular hemosiderin deposits in the brain cortex, the hippocampus, the basal ganglia, the corpus callosum, the thalamus, the septum and the midbrain in APP/ε2 (a), APP/ε3 (b), and APP/ε4 mice (c) (n = 5-11/group). Perivascular hemosiderin deposits were counted on every tenth brain coronal cross-section along the entire rostro-caudal axis of the brain. a through (c) p < 0.0001 (one-way analysis of variance); *p < 0.05, ***p < 0.001, and ****p < 0.0001, TY11-15 control vs. 10D5 mAb treatment for matching brain structures and APOE genotypes (Sidak’s post hoc test). For brain structures where the differences between TY11-15 control and 10D5 mAb treatment groups were not statistically significant p values are not shown. Differences between Age control and TY11-15 groups were non-significant for all structures (Sidak’s post hoc test); p values not shown on the graph. (PDF 419 kb

Additional file 1: Figure S1. of APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice

Comparative analysis of Aβ plaque load immunostained against N-terminal and central Aβ epitopes revealed no significant differences. a Representative microphotographs of coronal brain sections through the somatosensory cortex from the same TY11-15 control, and 10D5 mAb treated mice of APP/ε4 background, which were immunostained using HJ3.4 mAb directed against the N-terminus of Aβ and 4G8 mAb directed against the mid-portion of Aβ. b Unbiased analysis of the parenchymal Aβ plaque load in the brain cortex revealed by HJ3.4 and 4G8 immunostaining. Values represent mean ± SEM from 10 to 12 animals per group. b p < 0.0001 (one-way analysis of variance); ****p < 0.0001, TY11-15 control vs. 10D5 mAb treatment for matching anti-Aβ immunostains (Sidak’s post hoc test). Differences between HJ3.4 and 4G8 immunostaining in TY11-15 control and 10D5 mAb treatment groups were non-significant; not shown on the graph. Scale bar 50 μm (a). (PDF 423 kb

Individual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men - Fig 2

<p>The expected rate of HIV acquisition per 1000 discordant exposures for all MSM (Panel A), and for MSM who were currently using PrEP (Panel B) or not using PrEP at the time of exposure (Panel C), by the interaction of relative levels of condom-related risk compensation (RC) and PrEP medication adherence profile in which compensation occurred. Panel D shows the amount of person-time on PrEP per 100 possible person-weeks for susceptible MSM. The red line depicts RC in all four PrEP adherence profiles (high, medium, low, and non-adherent), the blue in the top three (high, medium, low) green in the top two (high and medium) and purple in the high only. The horizontal dashed lines shows a comparison of the two outcomes (incidence and PIA) if RC were not to occur (0% RC). All points summarize the empirical distribution of 250 simulations of each scenario.</p

Individual-Level Risk and Time on PrEP by Risk Compensation Level, by PrEP Adherence Level and Partnership Types, among US MSM.

<p>Individual-Level Risk and Time on PrEP by Risk Compensation Level, by PrEP Adherence Level and Partnership Types, among US MSM.</p

Schematic diagram showing the feedback loop between increased risk compensation, higher behavioral indications, and PrEP uptake among a four-person network over four time steps.

<p>At <i>t0</i>, Node 1 (N1) engages in condom unprotected anal intercourse (UAI) outside of a monogamous partnership (with N2 and N3), which leads to his indications for and uptake of PrEP at <i>t1</i>. In the risk compensation (RC) scenario, PrEP is associated with an increase in UAI (with N2), a PrEP non-user, whereas in the counterfactual no RC scenario, behavior remains the same as protected anal intercourse (PAI). At <i>t2</i>, N2 has engaged in UAI with N1 in the RC scenario, becomes indicated for PrEP, and uses it before initiating UAI with N4, an HIV-infected (status unknown) partner. In the <i>No RC</i> scenario, the PrEP uptake is delayed until <i>t3</i>, but N2 has already become infected by N4.</p

HIV Incidence Rate, Percent of Infections Averted, and Number Needed to Treat by Risk Compensation Level, by PrEP Adherence Level and Partnership Types, among US MSM.

<p>HIV Incidence Rate, Percent of Infections Averted, and Number Needed to Treat by Risk Compensation Level, by PrEP Adherence Level and Partnership Types, among US MSM.</p

Additional file 1: of High density methylation QTL analysis in human blood via next-generation sequencing of the methylated genomic DNA fraction

Supplementary Materials. (ZIP 58629 kb

Additional file 1 of Protocol for co-producing a framework and integrated resource platform for engaging patients in laboratory-based research

Additional file 1. Table S1. INVOLE’s Nine Principles for Deliberative Engagement